

**Minutes of the September 26, 2014
Pharmacy & Therapeutics (P&T) Committee Meeting
South Dakota Department of Social Services, Division of Medical Services**

Members Present

Richard Holm, MD; Bill Ladwig, RPh; Dana Darger, RPh; Mikel Holland, MD; James Engelbrecht, MD; Lenny Petrik; Michelle Baack, MD; Tim Soundy

DSS staff present

Mike Jockheck, RPh; Ann Schwartz, Dep. Director of Medical Services; Kirby Stone, Director of Medical Services

Administrative Business

The P&T meeting was called to order by D. Darger at 1:00pm. The minutes of the June 6, 2014 meeting were presented. M. Baack made a motion to approve. R. Holm seconded the motion. The motion was approved unanimously.

Prior Authorization Update and Statistics

The committee reviewed the prior authorization (PA) activity for August 2014. There were a total of 3,026 PA's processed in the month of August, with 99.70% of those requests responded to in less than eight hours. There were 2,344 (77%) requests received electronically and 682 (23%) requests received by fax.

Analysis of the top 15 Therapeutic Classes

The committee reviewed the Top 15 Therapeutic Classes by total cost of claims from 04/1/2014 – 06/30/2014. The top five classes were antipsychotics, respiratory and CNS stimulants, amphetamines, central nervous system agents, misc., and corticosteroids (respiratory tract). The top 15 therapeutic classes make up 40.41% of total claims. The Committee also reviewed the top 25 drugs based on total claims cost and number of claims. The top 25 drugs by claims cost make up 13.48% of total claims.

Treatment for Hepatitis C Review

The committee reviewed utilization information, PA forms, and treatment agreements for Hepatitis C therapy. A motion was made by M. Baack to accept the Treatment Agreement on page 14 of the P&T committee pack with the addendum 'I agree to have a blood test to monitor my viral load during and after treatment'. R. Holm seconded the motion. The motion was approved unanimously. The committee requested a box be added to the Hepatitis C PA forms asking if the patient is treatment naïve. The committee also suggested that all combination therapy requests and all retreatment therapy requests be reviewed by the medical director. M. Puryear, representing Gilead, spoke regarding Sovaldi. Jennifer Stoffel, representing Janssen, spoke regarding Olysio. A motion was made by R. Holm that all new drugs used to treat Hepatitis C will automatically be prior authorized. M. Baack seconded the motion. The motion was approved unanimously. A motion was made by B. Ladwig to include baseline HCV RNA and HCV RNA 4 weeks after treatment (SVR4) to the PA forms. R. Holm seconded the motion. The motion was approved unanimously.

Stimulant Use in Adults

The committee reviewed stimulant use in adults at the June meeting. It was requested that a review of the top prescribers be brought to the September meeting. J. Engelbrecht made a motion that a form be developed for stimulant use in adults. B. Ladwig seconded the motion. The motion was approved unanimously. A form will be brought to the December meeting for committee review.

Oral Allergen Extracts (Ragwitek, Grastek, Oralair)

The committee reviewed the oral allergen extracts prior authorization form. M. Baack made a motion to approve the form. R. Holm seconded the motion. The motion was approved unanimously.

Intuniv Review

The committee reviewed Intuniv clinical information. There was no public comment. This topic was tabled.

Transdermal Androgens Review

The committee reviewed transdermal androgens clinical information. There was no public comment. This topic was tabled.

Phosphate Binders Review

The committee reviewed phosphate binders clinical information. There was no public comment. This topic was tabled.

Zontivity Review

The committee reviewed Zontivity clinical information. There was no public comment. This topic was tabled.

Evzio Review

The committee reviewed Evzio clinical information. There was no public comment. B. Ladwig made a motion to place Evzio on prior authorization. T. Soundy seconded the motion. The motion was approved unanimously. A prior authorization form will be brought to the December meeting for committee review.

Otezlo Review

The committee reviewed Otezlo clinical information. There was no public comment. J. Engelbrecht made a motion to place Evzio on prior authorization. R. Holm seconded the motion. The motion was approved unanimously. A prior authorization form will be brought to the December meeting for committee review.

The next meeting is scheduled for December 12, 2014. R. Holm made a motion to adjourn the P&T Committee meeting. L. Petrik seconded the motion. The motion passed unanimously and the meeting was adjourned.